Recap, Your Docs are giving good advice. CDX-110 has completed multiple P2 trials and all are very consistently good. P3 will be the same, and a combo trial with Avastin will bring further efficacy to the Rindo story. But CDX-110/Rindo is only a very small part of the Celldex pipeline. You must look deeper.
Risk here at Celldex is about as mitigated as it can be in small pharma. They raised cash twice in 2013 and the pipeline is bursting with possibilities. So the combo of plenty of cash, great pipeline, and great management is one worth investing in. We are still sitting below the most recent share price offering. Soooooo, what are you waiting for? Do your DD and get cracking.
It is not hard to understand why millions of new shares where purchased at 24.50
They expect BIG returns, sooner rather than later.
""Every quarter, many money managers have to disclose what they've bought and sold via 13F filings. Their latest moves can shine a bright light on smart stock picks.
Today let's look at Columbia Wanger Asset Management. Founded in 1992, it's a subsidiary of Ameriprise Financial, managing mutual funds and serving investment companies, pension plans, and others. Its reportable stock portfolio totaled $26.1 billion in value as of Dec. 31, 2013.
So what does Columbia Wanger's latest quarterly 13F filing tell us? Here are a few interesting details:
The biggest new holdings are aerospace simulation specialist CAE and Groupon, Inc. Other new holdings of interest include Celldex Therapeutics (NASDAQ: CLDX ) and RE/MAX Holdings (NYSE: RMAX ) . Celldex shares more than tripled over the past year, making it one of 2013's best-performing biotechs, largely because of excitement over its late-stage brain cancer immunotherapy treatment, rindopepimut. The company has seen great promise in some of its formulations, with more in its pipeline. Cash burn, addressed via stock dilution, has been a concern, but with biotech companies, potential FDA approvals are the keys to ultimate success, and additional stock issuances aren't necessarily regrettable.""
He (the Analyst) likes Celldex both from a technical analysis and a pipeline analysis, and he basically suggested the argument that Biotech is out of favor is complete BS. He thinks Celldex will move up big from here.
Sentiment: Strong Buy
I new it, he is a KING!
People, he is KILLING the recovery. We should be growing by at least 4% over the last 4 years, but he is killing the willingness of small business to hire new employees.
"This past year was transformational for Celldex as we continued to make strides in cultivating one of the most robust, well-staged pipelines in immuno-oncology," said Anthony Marucci, President and Chief Executive Officer of Celldex Therapeutics. "We enter 2014 with five candidates in the clinic, including rindopepimut and glembatumumab vedotin in registration studies. By year-end, we anticipate the initiation of four new Celldex-sponsored clinical trials and several investigator-sponsored studies, including multiple combination regimens. These combination studies are designed to address what we believe is the next great opportunity for the immuno-oncology field--further unlocking the power of the immune system to deliver the greatest benefit to the largest population of patients possible. With last year's successful financing of the Company and current cash projected to fund our planned activities through 2016, we look forward to what we believe will be an exceptionally productive year."
This is really Strong language for Anthony Marucci.
"we look forward to what we believe will be an exceptionally productive year."
"""These combination studies are designed to address what we believe is the next great opportunity for the immuno-oncology field--further unlocking the power of the immune system to deliver the greatest benefit to the largest population of patients possible."""
I read this as they have very big plans for CDX-1127, and expect great results.
If they had negotiated with the loyal opposition from the beginning, details like the need for catastrophic plans would not have been overlooked. The HC industry already knew that was needed.
Rindo, and Celldex keep piling on the evidence of efficacy. What, is Celldex the red-headed step child? The Rodney Dangerfield of Pharma? How about some respect already? Those numbers are great!
Cancer 2.0, Immuno-Oncology
A new class of therapies that target Cancer Cells through the immune system
Coupled with traditional therapies
Potential prevention of relapses
He is a community organizer, and we made him president of the free world.
Long_vrts2, you are causing much stress for Lucky. He thinks he can keep betting on Celldex to the down side and win. I think he may be in error.
Ago, as you know, we agree on little, but when it comes to healthcare/insurance reform, you would be surprised by what I would say on the subject. I have spent much time thinking about the solution needed to cover all, and both parties have got to put away their special interest to do it. The old law and the current law are both highly flawed and politically motivated.
A catastrophic plan does not need to be written so poorly. That is a choice of the insurance lobby, and can be remedied by good law, like the rest of the HC insurance issues.
Lucky, you are an idiot. And a nervous idiot at that. These companies are complementary, not competitors at this point.
in the weeks just after last year's Leerink Swann Healthcare Conference? SP increased by $4 over four weeks and then kept rising until we hit high 30s. As a percentage increase, that was huge.
I suspect, with all the consolidation we have seen over the last four months, this conference will act as a launching point again.
Again, I say we test $50 around June heading into or just after ASCO. And I am not saying it couldn't happen earlier on significant news. IMHO
The report is an affirmation to legitimacy of the CDX-011 trial target which was previously reported on, and has now moved to the next trial phase. It's continued evidence that Celldex has a working drug in CDX-011.
Whipper, it does say good things about the future of Celldex.
These negative ninnies are shorts and will put down anything. Thanks for posting it.